白细胞清除术
医学
回顾性队列研究
内科学
相伴的
白血病
急性白血病
干细胞
遗传学
川地34
生物
作者
Xiang Zhang,Yuqing Tu,Juan Shen,Yufeng Feng,Houshi Ma,Lian Bai,Xiaoli Li,Zhihong Lin,Lingyun Dai,Fei‐Ran Gong,Tianyu Lu,Jiazi Zhou,Hanqing Chen,Quansheng Lv,Ziling Zhu,Changgeng Ruan
标识
DOI:10.1080/10428194.2022.2086246
摘要
Leukapheresis is an effective adjuvant therapy for leukemia patients with hyperleukocytosis, but few studies have reported recent data with modern modalities and comparisons among different leukemia types. We conducted a retrospective study on leukapheresis among 420 patients with AML, ALL and CML in four local centers. WBC counts decreased significantly (p < 0.001) postleukapheresis in all three cohorts. Clearance efficiency was higher in acute leukemia patients than CML patients (p < 0.01). Concomitant leukocytoreduction drugs improved WBC reduction only in AML patients (p < 0.05). Leukocyte, hemoglobin and platelet levels preleukapheresis might affect the clearance efficiency in AML and/or ALL patients. Hematological toxicities were the major concerns, but most of them were mild, and only 11 patients died of all causes within one week postleukapheresis. In conclusion, leukapheresis can safely reduce the leukemic burden, especially for patients with acute leukemias.
科研通智能强力驱动
Strongly Powered by AbleSci AI